ACADIA PHARMACEUTICALS INC (ACAD) Stock
2 members of Congress disclosed 2 trades in ACAD since 2019: 0 purchases and 2 sales, most recently Christopher L. Jacobs (sale, Jun 16, 2022). 7 of the hedge funds AlphaScala tracks reported ACAD in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Point72's at $61.56M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which members of Congress traded ACADIA PHARMACEUTICALS INC (ACAD)?
Most recent: Christopher L. Jacobs (sale, Jun 16, 2022); records start Feb 19, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-06-16 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2019-02-19 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all ACAD political trades →Which hedge funds own ACAD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 2.43M | $61.56M | -6% |
| Citadel Ken Griffin | 2.18M | $55.21M | +250% |
| Marshall Wace | 1.76M | $44.65M | +2216% |
| D.E. Shaw David Shaw | 1.70M | $42.96M | +133% |
| Renaissance Technologies Jim Simons (founder) | 1.28M | $32.45M | -26% |
| Millennium Management Israel Englander | 590K | $14.93M | -16% |
| Hussman Investment Trust John Hussman | 105K | $2.12M | +67% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are ACADIA PHARMACEUTICALS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 30, 26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 3.3K | $69K |
| Aug 6, 26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 5.0K | $145K |
| Aug 6, 26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 9.3K | $273K |
| Aug 5, 26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 5.8K | $170K |
| Jul 30, 26 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | SELL | 16.5K | $431K |
| Jul 30, 26 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | SELL | 50 | $1K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →ACAD price chart
Powered by TradingViewWhat does ACADIA PHARMACEUTICALS INC do?
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and commercializing medicines for central nervous system and neurological disorders. The company's commercial portfolio includes NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, an FDA-approved treatment for Rett syndrome available in oral solution and powder formulation (DAYBUE STIX). Acadia maintains a robust pipeline addressing significant unmet medical needs, with mid- to late-stage programs in development for Alzheimer's disease psychosis and Lewy body dementia psychosis, alongside earlier-stage neurological and rare disease programs. Founded in 1993 and headquartered in San Diego, California, the company serves patients, healthcare providers, and the global medical community by advancing therapeutic options for underserved patient populations in neurological and rare disease segments.